Research programme: vaginal infection antimicrobial peptides - C3J Therapeutics

Drug Profile

Research programme: vaginal infection antimicrobial peptides - C3J Therapeutics

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator C3 Jian
  • Developer C3J Therapeutics
  • Class Peptide fragments
  • Mechanism of Action Peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Candidiasis; Vaginitis

Most Recent Events

  • 29 Nov 2016 C3 Jian is now called C3J Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Candidiasis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vaginitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top